Y
Young I. Cho
Researcher at Drexel University
Publications - 268
Citations - 13499
Young I. Cho is an academic researcher from Drexel University. The author has contributed to research in topics: Fouling & Blood viscosity. The author has an hindex of 42, co-authored 266 publications receiving 12349 citations. Previous affiliations of Young I. Cho include California Institute of Technology & Thomas Jefferson University Hospital.
Papers
More filters
Journal ArticleDOI
Effect of mild atherosclerosis on flow resistance in a coronary artery casting of man
TL;DR: An in-vitro flow study was conducted in a mildly atherosclerotic main coronary artery casting of man using sugar-water solutions simulating blood viscosity, finding both pulsatile and steady flow data from the casting to be nearly equal to those from a straight, axisymmetric model.
Journal ArticleDOI
Decontamination of Surfaces From Extremophile Organisms Using Nonthermal Atmospheric-Pressure Plasmas
M. Cooper,Gregory Fridman,David Staack,Alexander Gutsol,Victor N. Vasilets,Shivanthi Anandan,Young I. Cho,Alexander Fridman,A. Tsapin +8 more
TL;DR: It is shown that nonthermal dielectric barrier discharge (DBD) plasma compromises the integrity of the cell membrane of Deinococcus radiodurans, an extremophile organism.
Journal ArticleDOI
Endothelial Shear Stress and Blood Viscosity in Peripheral Arterial Disease
TL;DR: This review examines the emerging role of endothelial shear stress and blood viscosity on the initiation and progression of atherosclerosis in peripheral arterial disease.
Journal ArticleDOI
A method of isolating surface tension and yield stress effects in a U-shaped scanning capillary-tube viscometer using a Casson model
TL;DR: In this article, a U-shaped scanning capillary-tube viscometer (SCTV) was used to measure the viscosity of distilled water and bovine blood.
Journal ArticleDOI
In vivo and in vitro anti-cancer activity of thermo-sensitive and photo-crosslinkable doxorubicin hydrogels composed of chitosan-doxorubicin conjugates
TL;DR: Doxorubsicin hydrogels containing doxorubicin conjugates can be employed as a novel injectable anti-cancer drug aiming to achieve sustained release of doxorbicin for several weeks against solid tumors.